ASCO 2010: Ovarian Cancer Research
Professor Stan Kaye — Institute of cancer Research, London, UK Prof Kaye talks about the future of ovarian cancer research. One area that is expected to be very important is research targeting the VEGF protein. A key presentation at ASCO 2010 has shown that a maintenance treatment of avastin, a targeted therapy that blocks VEGF, increases overall survival in ovarian cancer patients. The second area discussed is research into PARP inhibitors. After some spectacular initial results in women with BRCA mutations, a trial presented at ASCO 2010 has shown that olaparib is also effective at treating women with the more common high grade serous ovarian cancer.